GLP-1 drugs like Ozempic and Wegovy are celebrated for their powerful effects on weight loss and diabetes. But what happens when you stop taking them? A new study offers a sobering look at the consequences, and the findings go far beyond weight regain.
What Are GLP-1 Drugs?
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications that have transformed the treatment of type 2 diabetes and obesity. Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound) are among the most well-known. They work by mimicking a gut hormone that regulates appetite, blood sugar, and insulin. For patients, this often translates into significant weight loss, better blood sugar control, and a reduced risk of cardiovascular problems like heart attacks and strokes. These benefits have made them some of the most sought-after drugs in recent years.
The Discontinuation Dilemma
Despite their effectiveness, many patients stop taking GLP-1 medications. Studies show that a high percentage of users discontinue the drugs within the first year. The reasons are varied and often practical. For many, the out-of-pocket cost is a significant barrier, as insurance coverage can be inconsistent. Others struggle with persistent gastrointestinal side effects, such as nausea, vomiting, and diarrhea, which can impact their quality of life. Supply shortages and simply reaching a weight loss goal are other common reasons for stopping treatment. This high rate of discontinuation has prompted researchers to ask a critical question: are the benefits lost when the medication is stopped?
New Study Reveals Heart Risks Return
Recent research provides a stark answer. A large observational study of U.S. veterans with type 2 diabetes, published in BMJ Medicine, found that the significant heart-protective benefits of GLP-1 drugs diminish rapidly after discontinuation. The study tracked patients for three years and found that stopping the medication was linked to a progressive increase in the risk of major cardiovascular events. Another recent Italian study of over 80,000 patients with type 2 diabetes, published in The Lancet Regional Health Europe, reported a similar trend, finding that those who stopped treatment had roughly double the risk of a heart attack, stroke, or death compared to those who continued. While observational studies cannot prove direct cause and effect, the consistency of the findings is compelling.
Understanding the 'Metabolic Whiplash'
Researchers describe the effect of stopping these drugs as a kind of 'metabolic whiplash'. It’s not just that the protective effects disappear; the body’s systems can rebound quickly. When the medication is no longer present, appetite and 'food noise'—or constant thoughts about food—return with force. Blood pressure and cholesterol levels, which improve during treatment, can revert to their previous states. The cardiovascular risk doesn't just return to baseline; it appears to climb back alarmingly fast. The Washington University study found that after just one year off the drugs, the risk of a major cardiac event increased by 14%, and by two years, it was up 22%, nearly erasing all the benefits gained while on the medication. This suggests that what took years of treatment to build can be undone in a much shorter time.
A Chronic Treatment for a Chronic Condition
The key takeaway from this growing body of research is that obesity and diabetes are chronic conditions that often require long-term management. GLP-1 drugs are not a short-term cure but a continuous therapy. Just as one would not stop taking medication for high blood pressure and expect it to remain low, these drugs appear to require consistent use to maintain their benefits. Experts stress that the decision to start or stop these medications should be made in close consultation with a doctor. For patients who must discontinue for any reason, it is crucial to have a plan for what comes next, which might involve alternative therapies or a renewed focus on lifestyle interventions to manage long-term health risks.
















